![James Trager](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
James Trager
Chief Tech/Sci/R&D Officer at NKARTA, INC.
Net worth: 1 M $ as of 30/05/2024
Profile
James Trager is currently the Chief Scientific Officer at Nkarta, Inc. He previously worked as the Senior Vice President-Research & Development at Dendreon Corp from 2003 to 2019 and as a Research & Quality Control employee at Geron Corp from 1995 to 2003.
He holds a doctorate degree from the University of California, Berkeley and an undergraduate degree from St. John's College.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
NKARTA, INC.
0.21% | 17/06/2024 | 150,959 ( 0.21% ) | 1 M $ | 30/05/2024 |
James Trager active positions
Companies | Position | Start |
---|---|---|
NKARTA, INC. | Chief Tech/Sci/R&D Officer | 31/08/2016 |
Former positions of James Trager
Companies | Position | End |
---|---|---|
DENDREON CORPORATION | Chief Tech/Sci/R&D Officer | 30/11/2019 |
GERON CORPORATION | Corporate Officer/Principal | 01/01/2003 |
Training of James Trager
St. John's College | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
NKARTA, INC. | Health Technology |
GERON CORPORATION | Health Technology |
Private companies | 1 |
---|---|
Dendreon Corp.
![]() Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- James Trager